Edition:
United Kingdom

Novavax Inc (NVAX.OQ)

NVAX.OQ on NASDAQ Stock Exchange Global Select Market

4.98USD
14 Jun 2019
Change (% chg)

$-0.22 (-4.23%)
Prev Close
$5.20
Open
$5.09
Day's High
$5.24
Day's Low
$4.92
Volume
166,243
Avg. Vol
185,517
52-wk High
$51.60
52-wk Low
$4.65

Latest Key Developments (Source: Significant Developments)

Novavax Q1 Loss Per Share $0.11
Thursday, 2 May 2019 

May 2 (Reuters) - Novavax Inc ::NOVAVAX REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.11.Q1 EARNINGS PER SHARE ESTIMATE $-0.11 -- REFINITIV IBES DATA.Q1 REVENUE $4.0 MILLION VERSUS REFINITIV IBES ESTIMATE OF $3.9 MILLION.NOVAVAX - AS OF MARCH 31, 2019, HAD $108.7 MILLION IN CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES & RESTRICTED CASH, VERSUS $103.9 MILLION AS OF DEC 31, 2018.  Full Article

Novavax Reports Q1 Loss Per Share $0.11
Thursday, 2 May 2019 

May 2 (Reuters) - Novavax Inc ::NOVAVAX REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.11.Q1 REVENUE $4.0 MILLION VERSUS REFINITIV IBES ESTIMATE OF $3.9 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.11 -- REFINITIV IBES DATA.  Full Article

Novavax Reports Q4 Loss Per Share $0.13
Monday, 18 Mar 2019 

March 18 (Reuters) - Novavax Inc ::NOVAVAX REPORTS FOURTH QUARTER AND YEAR-END 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.13.Q4 REVENUE $6.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $7.1 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.12 -- REFINITIV IBES DATA.NOVAVAX - AS OF DEC 31, 2018, HAD $103.9 MILLION IN CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AND RESTRICTED CASH, VERSUS $186.4 MILLION AS OF DEC 31, 2017.  Full Article

Novavax Q3 Revenue $7.7 Mln Vs I/B/E/S View $9.4 Mln
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Novavax Inc ::NOVAVAX REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.12.Q3 EARNINGS PER SHARE VIEW $-0.12 -- THOMSON REUTERS I/B/E/S.Q3 REVENUE $7.7 MILLION VERSUS I/B/E/S VIEW $9.4 MILLION.ON TRACK TO MEET 2018 OBJECTIVES.AS OF SEPT 30, CO HAD $145.6 MILLION IN CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AND RESTRICTED CASH.  Full Article

Novavax Says Co And Cadila Pharmaceuticals Entered Agreement To Permit CPLB To Develop Some Cadila Biological Products
Tuesday, 24 Jul 2018 

July 24 (Reuters) - Novavax Inc ::NOVAVAX - ON JULY 18, CO AND CADILA PHARMACEUTICALS ENTERED INTO SECOND AMENDED, RESTATED JOINT VENTURE AGREEMENT FOR CPL BIOLOGICALS PRIVATE LIMITED.NOVAVAX - PURSUANT TO AGREEMENT, CO, CADILA AMENDED AND RESTATED CERTAIN TERMS RELATED TO FIRST AMENDED AND RESTATED JOINT VENTURE AGREEMENT FOR CPLB.NOVAVAX - AGREEMENTS PERMIT CPLB TO DEVELOP SOME CADILA BIOLOGICAL PRODUCTS & TO DEVELOP CERTAIN PRODUCTS USING CO'S NANOPARTICLE VACCINE PRODUCTION.NOVAVAX-AGREEMENTS PERMIT CPLB TO DEVELOP SOME CADILA BIOLOGICAL PRODUCTS USING CO'S ANTIGEN SPECIFIC SEED DEVELOPMENT, PROTEIN EXPRESSION, OTHERS.  Full Article

Novavax Inc Promotes John Trizzino To CFO Role
Wednesday, 14 Mar 2018 

March 14 (Reuters) - Novavax Inc ::NOVAVAX PROMOTES JOHN J. TRIZZINO TO EXPANDED ROLE AS CHIEF BUSINESS OFFICER AND CHIEF FINANCIAL OFFICER.NOVAVAX - TRIZZINO HAS BEEN SERVING AS SVP, COMMERCIAL OPERATIONS, SINCE 2014.  Full Article

Novavax Inc Q4 Loss Per Share $0.16
Wednesday, 14 Mar 2018 

March 14 (Reuters) - Novavax Inc ::NOVAVAX PROVIDES CORPORATE UPDATE AND REPORT OF FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.16.Q4 EARNINGS PER SHARE VIEW $-0.15 -- THOMSON REUTERS I/B/E/S.Q4 REVENUE $10.4 MILLION VERSUS $5.4 MILLION.Q4 REVENUE VIEW $8 MILLION -- THOMSON REUTERS I/B/E/S.JOHN J. TRIZZINO APPOINTED CHIEF BUSINESS OFFICER AND CHIEF FINANCIAL OFFICER.  Full Article

Novavax CEO Stanley Erck reports open market purchase of 100,000 co's common shares
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Novavax Inc :Novavax Inc says CEO Stanley Erck reports open market purchase of 100,000 co's common shares at average price of $1.13per share on november 9 - sec filing.  Full Article

Novavax reports Q3 loss per share $0.15
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Novavax Inc ::Novavax reports third quarter 2017 financial results.Q3 loss per share $0.15.Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.Q3 revenue $8.4 million versus $3.2 million.Q3 revenue view $6.4 million -- Thomson Reuters I/B/E/S.  Full Article

Novavax Q3 loss per share $0.15
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Novavax Inc ::Novavax reports third quarter 2017 financial results.Q3 loss per share $0.15.Q3 revenue $8.4 million versus $3.2 million.Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.Q3 revenue view $6.4 million -- Thomson Reuters I/B/E/S.Novavax - ‍as of Sept 30, 2017, co had $172.6 million in cash, cash equivalents and marketable securities, compared to $235.5 million as of Dec 31, 2016​.  Full Article

UPDATE 1-Enanta's lung infection therapy succeeds in mid-stage trial

June 14 Enanta Pharmaceuticals Inc said on Friday its treatment for a highly contagious respiratory infection met the main goal of reducing virus levels in the body in a mid-stage study.